CLPP-2068

• Description :

  CLPP-2068 is the orally active activator for human caseinolytic protease P (HsClpP) with an EC50 of 50.4 nM. CLPP-2068 exhibits anti-proliferative efficacy in OCI-LY10 cancer cell with an IC50 of 5.2 nM. CLPP-2068 decreases mitochondrial membrane potential, increases mitochondrial ROS levels, and induces mitochondrial dysfunction. CLPP-2068 arrests the cell cycle at G1 phase, and induces apoptosis in cell OCI-LY10. CLPP-2068 exhibits antitumor activity in mouse xenograft models[1].

• UNSPSC :

  12352005

• Target :

  Apoptosis; ClpP; Reactive Oxygen Species (ROS)

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

• Field of Research :

  Cancer

• Purity :

  97.41

• Solubility :

  DMSO : 33.33 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C1NC(NCC2=CC=C(Br)C=C2)=NC3=C1CN([C@H](C)C3)CC4=CC(C#N)=CC=C4

• Molecular Formula :

  C23H22BrN5O

• Molecular Weight :

  464.36

• References & Citations :

  [1]Sun M, et al., Harnessing the Magic Methyl Effect: Discovery of CLPP-2068 as a Novel HsClpP Activator for the Treatment of Diffuse Large B-Cell Lymphoma. J Med Chem. 2025 Feb 27;68 (4) :4287-4307.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported